Ibandronate sodium monohydrate

产品说明书

Print
Chemical Structure| 138926-19-9 同义名 : 伊班膦酸钠一水合物 ;BM-210955; RPR-102289A; Sodium trihydrogen (1-hydroxy-3-(methylpentylamino)propylidene)diphosphonate, monohydrate; Ibandronate sodium; Boniva; Ibandronate (sodium hydrate)
CAS号 : 138926-19-9
货号 : A183108
分子式 : C9H24NNaO8P2
纯度 : 98%
分子量 : 359.23
MDL号 : MFCD00912167
存储条件：

Pure form Keep in dark place, inert atmosphere, 2-8°C

In solvent -20°C:3-6个月-80°C:12个月
溶解度 :

H2O: 25 mg/mL(69.59 mM)，配合低频超声助溶
动物实验配方：
生物活性
描述 Ibandronate Sodium Monohydrate is a potent nitrogen-containing bisphosphonate, primarily utilized in the treatment of osteoporosis. It operates by targeting the bone metabolism to prevent bone loss. In research focused on endothelial cells, Ibandronate at concentrations between 1.25 and 2 μM notably reduces cell growth. At 2 μM, it also significantly hampers the formation of capillary-like structures and induces apoptosis in these cells. Furthermore, Ibandronate increases VEGF expression in endothelial cells in a dose-dependent manner when administered at concentrations below 100 μM[1]. In studies involving prostate cancer cell lines, including LNCaP and PC-3, Ibandronate shows a dose-dependent inhibitory effect on cell growth at concentrations below 100 μM[2]. For clinical applications in osteoporosis, Ibandronate administered daily at 2.5 mg or intermittently at 20 mg every other day for 12 doses every three months, significantly reduces the risk of new morphometric vertebral fractures by 62% and 50%, respectively, over a period of three years. Additionally, these dosing regimens lead to a significant and progressive increase in bone mineral density (BMD) of the lumbar spine by 6.5% and 5.7%, respectively, in osteoporotic women following three years of treatment[3]. In ovariectomized rats, a model for post-menopausal osteoporosis, Ibandronate administered subcutaneously at doses up to 125 mg/kg results in a dose-dependent increase in bone mineral density, trabecular bone volume, trabecular number, maximum load to failure (Fmax), and yield load in long bones and vertebrae. It also fully prevents the increase in trabecular separation observed in these rats[4].
实验方案
1mg 5mg 10mg

1 mM

5 mM

10 mM

2.78mL

0.56mL

0.28mL

13.92mL

2.78mL

1.39mL

27.84mL

5.57mL

2.78mL
参考文献

[1]Morgan, C., S. Jeremiah, and J. Wagstaff, Metronomic administration of ibandronate and its anti-angiogenic effects in vitro. Microvasc Res, 2009. 78(3): p. 453-8.

[2]Epplen, R., et al., Differential effects of ibandronate, docetaxel and farnesol treatment alone and in combination on the growth of prostate cancer cell lines. Acta Oncol, 2011. 50(1): p. 127-33.

[3]Chesnut, I.C., et al., Effects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosis. J Bone Miner Res, 2004. 19(8): p. 1241-9.

[4]Bauss, F., et al., Effects of treatment with ibandronate on bone mass, architecture, biomechanical properties, and bone concentration of ibandronate in ovariectomized aged rats. J Rheumatol, 2002. 29(10): p. 2200-8.